Goat Pox Virus

Overview and Taxonomy of Goat Pox Virus (GTPV)

Taxonomic Lineage and Phylogenetic Position

Goat pox virus (GTPV) is a member of the genus Capripoxvirus (CaPV) within the subfamily Chordopoxvirinae of the family Poxviridae, a lineage of large, enveloped, double-stranded DNA viruses renowned for their complex virion architecture and capacity for genetic recombination [2, 17]. The genus Capripoxvirus comprises three closely related but distinct viral species: GTPV, sheep pox virus (SPPV), and lumpy skin disease virus (LSDV), the etiological agents of goat pox, sheep pox, and lumpy skin disease of cattle, respectively [4, 5, 14, 16]. The evolutionary and antigenic intimacy among these three viruses is underscored by nucleotide sequence similarities that can approach 97% across large genomic regions, a fact that has profound implications for both pathogenesis and vaccinology [9, 17]. Template from the World Organisation for Animal Health (WOAH) guidelines recognizes all three as notifiable, transboundary pathogens of critical economic significance, with GTPV specifically classified under WOAH-listed diseases due to its capacity for rapid international spread and severe trade restrictions.

The taxonomic delineation of GTPV from SPPV and LSDV has historically been challenging, relying on a combination of host species specificity, genomic markers, and increasingly sophisticated molecular phylogenetic analyses. Early classification efforts were primarily based on clinical presentation and host range: GTPV was considered the agent specifically adapted to goats, SPPV to sheep, and LSDV to cattle [5, 14]. However, this strict host specificity paradigm has been substantially revised in recent decades. Epidemiological and phylogenetic evidence has demonstrated that cross-species infections are not merely rare events but occur with sufficient frequency to complicate diagnosis and control, particularly in regions where multiple capripoxviruses co-circulate [4, 14].

Molecular Characterization and Genetic Markers

Molecular characterization of GTPV has been revolutionized by the application of targeted gene sequencing and whole-genome phylogenetic analyses. Three genomic loci have emerged as the principal targets for species-level differentiation: the P32 gene (encoding a major envelope protein), the RPO30 gene (encoding the 30 kDa RNA polymerase subunit), and the GPCR gene (encoding a G protein-coupled receptor homolog) [5, 11]. These regions harbor species-specific single nucleotide polymorphisms (SNPs) and length polymorphisms that enable reliable discrimination among capripoxvirus species. Phylogenetic analyses of the P32 gene have consistently demonstrated that GTPV isolates form a monophyletic clade distinct from SPPV and LSDV, with nucleotide identity among global GTPV strains typically exceeding 99% at the amino acid level [3, 5]. This remarkable genetic conservation suggests that GTPV has undergone relatively recent diversification from a common ancestor, possibly reflecting host adaptation events followed by rapid geographic dissemination.

The utility of the RPO30 gene for differential diagnosis is particularly noteworthy. PCR amplification of the RPO30 locus yields amplicons of characteristic sizes: approximately 172 base pairs for SPPV and 152 base pairs for GTPV, a difference that facilitates rapid gel-based differentiation [11]. This approach has been validated across diverse geographic isolates and provides a robust molecular tool for discriminating infections in clinical settings where serological cross-reactivity precludes accurate diagnosis [11]. More recently, real-time PCR assays utilizing high-resolution melting (HRM) curve analysis have been developed to differentiate GTPV, SPPV, field LSDV, and vaccine strains of LSDV based on melting temperature differences as subtle as 0.6 to 1.3°C [7]. The HRM assay targeting the LSDV010 ORF region yields characteristic melting peaks of 73.61 ± 0.04°C for GTPV, 74.24 ± 0.06°C for SPPV, and 74.56 ± 0.04°C for field LSDV, offering a rapid, high-throughput diagnostic capability [7].

Phylogenetic Geography and Global Lineages

Phylogenetic studies of GTPV isolates from Africa, Asia, and the Middle East have revealed a pattern of geographic clustering that reflects both historical dissemination and contemporary trade routes. A comprehensive analysis of full-length P32, RPO30, and GPCR gene sequences from Saudi Arabian isolates collected between 2013 and 2017 classified six capripoxvirus strains into five SPPV and one GTPV, with nucleotide identities ranging from 90% to 100% for GPCR across global reference strains [5]. The Vietnamese strain (MN317561/VNUAGTP1), isolated during a re-emergence event in North Vietnam after a decade of silence, demonstrated 99.6% nucleotide and 99.3% amino acid identity to reference GTPV strains from China, India, and Pakistan, clustering firmly within the Asian clade and suggesting a South Chinese origin for the outbreak [3]. This phylogenetic positioning is consistent with a model of regional circulation wherein GTPV strains from neighboring countries share recent common ancestors, implying cross-border transmission through animal movement.

The genetic homogeneity among GTPV isolates from geographically disparate regions, Vietnam, Pakistan, India, China, Egypt, and beyond, contradicts the notion of highly localized viral evolution [3, 5, 8, 10]. Instead, GTPV appears to maintain a stable genomic backbone with limited antigenic drift, likely constrained by the functional requirements of a large DNA virus with proofreading polymerase activity. This stability has important practical consequences: vaccines developed from one GTPV strain are generally efficacious against heterologous strains, a property exploited in the development of cross-protective capripoxvirus vaccines used against LSDV and SPPV [1, 13, 19].

Antigenic Relationships and Cross-Species Infection

The antigenic relatedness among capripoxviruses is a defining biological feature with profound implications for vaccine development and disease control. Neutralization assays demonstrate that polyclonal antisera raised against GTPV efficiently neutralize SPPV and LSDV, and vice versa, a phenomenon that underpins the use of heterologous vaccines [1, 9, 15, 17]. For example, the live attenuated GTPV vaccine strain G20-LKV, derived from a goat pox isolate, has been successfully employed to protect cattle against LSDV challenge and sheep against SPPV challenge, with immunizing doses as low as 15,000 TCID50 conferring sterile immunity in cattle [1]. This cross-protection is attributable to the highly conserved immunodominant epitopes present in the envelope proteins of all three capripoxvirus species, particularly those involved in virus neutralization.

However, the antigenic cross-reactivity that enables heterologous vaccination simultaneously complicates serological diagnosis. Standard serological tests, including virus neutralization tests and enzyme-linked immunosorbent assays (ELISAs), cannot differentiate between animals infected with GTPV, SPPV, or LSDV, nor can they distinguish vaccinated from naturally infected animals [9, 17]. This limitation has spurred the development of differentiating infected from vaccinated animals (DIVA) strategies, such as the use of synthetic LSDV-specific proteins as ELISA antigens to detect only LSDV-infected cattle while avoiding cross-reaction with GTPV-vaccinated animals [9]. The development of such assays is critical for maintaining surveillance programs in areas where capripoxvirus vaccination is practiced.

Host Range and Species Specificity

While GTPV is traditionally considered a virus of goats, its host range is broader than historical accounts suggest. Molecular epidemiological studies have repeatedly documented GTPV infection in sheep, with some outbreaks affecting both species simultaneously [12, 18]. In a comprehensive investigation of poxvirus outbreaks in Northwest Ethiopia, all 19 clinical samples collected from both sheep and goats were identified as GTPV by PCR, indicating that sheep in those outbreaks were infected with goat pox virus rather than sheep pox virus [18]. Similarly, serosurveys in Uganda found that sheep exhibited higher seroprevalence (12%) for capripoxvirus antibodies than goats (10%), although it was not always possible to determine which viral species was responsible [12]. These findings challenge the neat taxonomic separation of GTPV and SPPV and suggest that host preference is not absolute.

The biological basis for this cross-species infectivity may reside in the viral genome's capacity for adaptive mutation, particularly in genes encoding host range factors. Sequence analysis of the P32 gene from field isolates infecting sheep has revealed no consistent genetic signature that distinguishes sheep-infecting from goat-infecting GTPV strains, implying that host switching can occur without extensive genomic change [5]. This plasticity, combined with the high viral loads shed in scabs and secretions, facilitates interspecies transmission in mixed-species flocks, which are common across Africa, Asia, and the Middle East [2, 12]. The World Health Organization (WHO) and WOAH both emphasize that capripoxviruses are not zoonotic, alleviating human health concerns but underscoring the purely agricultural threat they pose.

Viral Morphology and Genomic Architecture

Morphologically, GTPV conforms to the classic poxvirus structure: a brick-shaped or ovoid virion measuring approximately 300 × 270 × 200 nm, with an outer envelope derived from the host cell membrane and an internal core containing the linear double-stranded DNA genome [11, 17]. The genome of GTPV is approximately 150 kilobase pairs in length, encoding over 140 open reading frames that encompass genes for viral replication, host immune evasion, and virulence [6, 17]. Electron microscopy of GTPV-infected cell cultures demonstrates characteristic negatively stained, oval-shaped virus particles with an irregular surface pattern reflecting the arrangement of surface tubules [11]. The large, stable genome, combined with cytoplasmic replication, makes GTPV an attractive platform for recombinant vaccine development. The thymidine kinase gene has been successfully used as a insertion site for foreign antigens, such as Brucella outer membrane protein 25, enabling the construction of bivalent vaccines that protect against both GTPV and brucellosis [6].

Implications for Disease Ecology

The taxonomic and phylogenetic understanding of GTPV directly informs disease ecology and control strategies. The high degree of genetic and antigenic relatedness among capripoxviruses means that surveillance and vaccination programs must consider the entire genus rather than individual species. Outbreaks initially suspected to be sheep pox may, upon molecular typing, be attributable to GTPV, altering the choice of vaccine strain [5, 18]. Moreover, the use of GTPV-based vaccines for LSDV control in cattle and SPPV control in sheep has become standard practice in many endemic regions, leveraging the cross-protective capacity of the virus while also introducing live GTPV into non-goat hosts [1, 13, 19]. This practice, while effective, introduces potential ecological complexities: vaccine virus shed from vaccinated cattle could theoretically infect naive goats, maintaining viral circulation even in the absence of overt goat pox outbreaks.

The stability of the GTPV genome across time and space, evidenced by >99% sequence identity among strains collected decades apart on different continents, suggests that the virus is not undergoing rapid antigenic evolution. This stability is a double-edged sword: it enables the long-term efficacy of existing vaccines but also implies that any emergence of vaccine escape mutants would represent a major evolutionary shift requiring close surveillance.

Molecular Pathogenesis and Virulence Determinants of GTPV

The molecular pathogenesis of goat pox virus (GTPV) is a multifaceted process orchestrated by a complex arsenal of virulence determinants encoded within its large, double-stranded DNA genome. As a member of the Capripoxvirus genus within the Poxviridae family, GTPV shares substantial genomic architecture and pathogenic strategies with sheeppox virus (SPPV) and lumpy skin disease virus (LSDV), yet exhibits distinct host tropism and disease manifestations in goats [17]. Understanding the molecular underpinnings of GTPV virulence is not merely an academic exercise; it is fundamental to the rational design of attenuated vaccines, the development of differential diagnostic assays, and the elucidation of cross-species transmission dynamics that have significant implications for global livestock health and trade [1, 5, 9]. The World Organisation for Animal Health (WOAH) classifies capripoxviruses as notifiable pathogens due to their severe economic impact, and the Food and Agriculture Organization (FAO) emphasizes the need for molecular-level surveillance to inform control strategies in endemic regions.

Genome Organization and Key Virulence Loci

The GTPV genome, approximately 150 kbp in size, is organized into a central conserved core region flanked by variable terminal inverted repeat (ITR) sequences. These ITR regions are of particular interest in virulence determination, as they harbor genes involved in host range, immune evasion, and viral replication efficiency. Sequence analyses of the ITR-based inverted terminal repeats have revealed sufficient genetic divergence between GTPV and SPPV to allow for rapid, specific molecular differentiation through loop-mediated isothermal amplification (LAMP) assays, underscoring the functional importance of these genomic termini in species-specific pathogenesis [21].

Within the core genome, a suite of genes encoding structural proteins, immunomodulatory factors, and enzymes essential for DNA replication and virion assembly constitute the foundational machinery for infection. The strategic use of the thymidine kinase (TK) gene locus as a site for foreign gene insertion in recombinant GTPV vectors demonstrates that this region, while non-essential for viral replication in vitro, plays a role in virulence attenuation in vivo [6]. This is consistent with the broader poxvirus paradigm where TK gene disruption reduces nucleotide scavenging capacity in non-dividing cells, thereby limiting viral spread in differentiated tissues.

The P32 Gene: A Major Immunodominant Protein and Virulence Factor

The P32 gene encodes a 32-kDa envelope protein that is a primary target of the host humoral immune response and has been extensively exploited for molecular epidemiology and phylogenetic tracing of GTPV. Nucleotide sequence analysis of the P32 gene from a newly emerged Vietnamese GTPV strain (MN317561/VNUAGTP1) revealed 99.6% nucleotide identity and 99.3% amino acid identity with reference strains circulating in China, India, and Pakistan, confirming its conservation as a critical structural component that is likely under strong functional constraint [3].

Beyond its diagnostic utility, the P32 protein is a key determinant of viral entry and cell-to-cell spread. Its surface exposure renders it a major antigen for neutralizing antibodies, and variability in P32 sequence across capripoxvirus species has been leveraged to differentiate GTPV from SPPV and LSDV. Phylogenetic analysis of the P32, RPO30, and GPCR genes in Saudi Arabian isolates confirmed that while P32-based trees correctly clustered the six detected capripoxviruses into five SPPVs and one GTPV, the resolution of species-specific clades was enhanced when P32 data were combined with other gene targets [5]. This suggests that P32 alone, while highly immunogenic, may not fully capture the nuanced host-range determinants that distinguish GTPV from its closest relatives.

The P32 gene has also been the target of molecular characterization in field outbreaks in Pakistan, where PCR amplification of P32 fragments (89 and 390 bp) from clinical samples confirmed GTPV infection in goat populations, with infants aged 2-10 months showing the highest prevalence (25-31.25%) [8]. In Egypt, isolation of GTPV from skin scabs and chorioallantoic membrane (CAM) cultures was followed by P32-based PCR yielding products of 89 bp (primer 1) and 390 bp (primer 2), validating the P32 gene as a robust target for molecular detection even in degraded field samples [10].

The RPO30 Gene and Host-Specific Pathogenesis

The RNA polymerase 30 kDa subunit gene (RPO30) has emerged as one of the most reliable molecular markers for differentiating GTPV from SPPV, owing to a consistent size polymorphism: GTPV yields a 152 bp amplicon, while SPPV yields a 172 bp product. This difference originates from a 20 bp deletion in the GTPV RPO30 gene, which has been validated across multiple geographic isolates and serves as a molecular signature of host adaptation [11].

The functional implications of this deletion are profound. The RPO30 gene product is a component of the viral DNA-dependent RNA polymerase complex, which is essential for transcription of early, intermediate, and late viral genes. A truncation or structural alteration in the RPO30 protein could subtly alter promoter recognition kinetics or elongation efficiency, potentially influencing the replication rate and tissue tropism that distinguishes the generalized, often fatal, disease in goats from the more variable presentation in sheep. Field investigations in the Giza Governorate of Egypt demonstrated that RPO30-based PCR was 90% sensitive in detecting capripoxviruses from clinical samples, with the 152 bp GTPV-specific band clearly differentiating goat-derived viruses from sheep-derived isolates [11]. Similarly, in Pakistan, RPO30 amplification (151 bp) was used in conjunction with P32 assays to confirm the identity of goat pox virus isolates [10].

This molecular marker has been incorporated into multiplex real-time PCR systems capable of simultaneously detecting and differentiating GTPV, SPPV, and LSDV. By designing specific probes for each species based on the RPO30 gene region, Wang et al. (2021) achieved a limit of detection of 10² copies of target DNA with no cross-reactivity against other pathogens causing similar clinical signs [4]. The robustness of RPO30-based differentiation has also been confirmed by high-resolution melting (HRM) PCR, which identifies GTPV amplicons by a distinct melting temperature of 73.61 ± 0.04°C, clearly separated from SPPV (74.24°C), field LSDV (74.56°C), and vaccine LSDV (74.95°C) [7].

GPCR Gene and Host Range Determinants

The G protein-coupled receptor (GPCR) gene homologue in capripoxviruses is a key modulator of host range and cellular signaling. Phylogenetic analysis of the GPCR gene from Saudi Arabian capripoxvirus isolates revealed the highest degree of sequence divergence among the three commonly targeted genes (P32, RPO30, GPCR), with nucleotide identities ranging from 90% to 99% compared to worldwide reference strains [5]. This variability is consistent with the role of GPCR homologues in poxvirus pathogenesis: these proteins mimic cellular chemokine receptors and can subvert the host immune response by sequestering chemokines, altering leukocyte trafficking, and promoting viral dissemination.

The GPCR gene's higher sequence diversity compared to P32 and RPO30 reflects ongoing selective pressure from the host immune system and adaptation to different ruminant species. This makes GPCR a valuable tool for tracing the molecular epidemiology of cross-species transmission events. The documented ability of certain capripoxvirus strains to infect both sheep and goats, despite the general host specificity, likely involves mutations in GPCR and other host-range genes that expand the viral tropism [5, 14]. The recent re-emergence of GTPV in Vietnam after a decade of silence, traced phylogenetically to strains from South China, underscores how GPCR and other gene markers can reveal the geographic dissemination pathways of virulent strains [3].

Molecular Mechanisms of Immune Evasion and Virulence

GTPV, like other poxviruses, encodes a battery of immunomodulatory proteins that subvert host antiviral defenses. The ability of GTPV to replicate to high titers in the skin and produce characteristic nodular lesions is contingent upon its capacity to evade both innate and adaptive immune responses. The large double-stranded DNA genome encodes multiple virulence factors that interfere with interferon signaling, apoptosis, and inflammatory cytokine cascades.

One of the critical determinants of virulence is the virus's ability to establish a localized infection in the skin and mucous membranes before disseminating systemically. The virus enters through abrasions or via direct contact with infected secretions, where it initially replicates in epithelial cells. The formation of papules, vesicles, pustules, and scabs is a direct result of viral cytopathology and the associated inflammatory response. Histopathological examination of pox lesions reveals ballooning degeneration of keratinocytes, intracellular edema, and the formation of characteristic intracytoplasmic inclusion bodies (Bollinger bodies) [14, 22].

The systemic phase of GTPV infection is characterized by viremia, fever, and the development of secondary lesions in internal organs such as the lungs, liver, and spleen. The severity of systemic involvement is a direct correlate of viral virulence. Outbreaks in Vietnam resulted in a mortality rate of 6.5%, while in Ethiopia, mortality can range from 10% to 85%, approaching 100% in fully susceptible naive populations [3, 16]. These differences in clinical outcome are likely mediated by allelic variations in key virulence genes that control the balance between viral replication and host immune clearance.

Role of Viral Proteases and Structural Proteins in Pathogenesis

The ORF103 gene, encoding a major structural protein involved in virion morphogenesis, has been molecularly characterized in SPPV outbreaks in India, but its homologue in GTPV is similarly essential for the production of infectious progeny. Sequence analysis of the ORF103 gene from field isolates revealed 99-100% identity with reference strains, indicating strong evolutionary conservation [22]. The protein product of ORF103 is a component of the mature virion and is critical for the assembly of the viral membrane and the packaging of the core genome. Disruption of this gene in recombinant virus constructs would severely impair viral replication, confirming its status as an essential virulence determinant.

Viral Persistence and Environmental Resistance as Indirect Virulence Factors

While not a direct molecular determinant of host cell tropism, the remarkable environmental stability of GTPV contributes significantly to its pathogenic success. The virus can survive for up to six months in dried scabs shed from infected animals [2, 20]. This environmental persistence is rooted in the structural resilience of the poxvirus virion, which possesses a lipid envelope and a complex proteinaceous core that resists desiccation, heat, and many common disinfectants. The scab material, containing high concentrations of infectious virus particles, serves as a prolonged source of contamination for feed, water, soil, and fomites, facilitating indirect transmission long after the active clinical phase has resolved [2].

The virucidal efficacy of disinfectants such as GAN, Dexid-400, and sodium hydroxide against the capripoxvirus causative agent has been demonstrated, but the hardiness of the virus in organic material necessitates rigorous cleaning protocols for outbreak containment [20]. This environmental stability amplifies the effective virulence of GTPV by extending the window of transmission and increasing the probability of exposure in naive populations.

Epidemiology and Risk Factors for Goat Pox Virus Infection

The epidemiology of goat pox virus (GTPV) infection is a complex interplay of viral pathogenicity, host susceptibility, environmental resilience, and anthropogenic factors that collectively determine the spatiotemporal distribution and intensity of outbreaks. As a member of the genus Capripoxvirus within the family Poxviridae, GTPV shares antigenic and genetic kinship with sheeppox virus (SPPV) and lumpy skin disease virus (LSDV), a relationship that profoundly complicates epidemiological investigations and control measures [17]. The disease is classified as a WOAH (World Organisation for Animal Health)-notifiable transboundary infection, underscoring its capacity for rapid international spread and severe economic consequences [12]. Understanding the nuanced epidemiological patterns and the multifactorial risk architecture that governs infection and dissemination is paramount for designing effective surveillance and intervention strategies.

Global Distribution and Spatiotemporal Patterns

Goat pox is not a disease of the past; it is a dynamic, re-emerging threat across Africa, Asia, and parts of Europe. Historically enzootic in the Middle East, the Indian subcontinent, and much of Africa, the virus has demonstrated a concerning capacity for geographic expansion. The re-emergence of GTPV in North Vietnam after a decade of silence, affecting over 1,800 goats with a 6.5% mortality rate, serves as a stark reminder of its potential for resurgence [3]. Phylogenetic analysis of the Vietnamese strain, clustering with isolates from China, India, and Pakistan, strongly suggests transboundary dissemination of a common Asian lineage, likely facilitated by unregulated animal movements [3]. Similarly, the first genetic characterization of capripoxviruses in Saudi Arabia between 2013 and 2017 revealed the circulation of both SPPV and GTPV, emphasizing the co-endemic nature of these pathogens in the Arabian Peninsula [5]. In Africa, the disease is pervasive. Studies in Ethiopia reveal a staggering burden, with 663 outbreaks reported in the Eastern Amhara region alone over a seven-year period (2013-2019), and retrospective data from the entire Amhara region documenting 182 goat pox outbreaks with over 10,000 cases and nearly 1,000 deaths between 2010 and 2014 [28, 30]. The situation in the Republic of Chad is similarly characterized by periodic, poorly documented outbreaks, highlighting a critical gap in surveillance infrastructure [2].

The temporal distribution of outbreaks is not random. A robust analysis of seven years of data from Ethiopia identified a distinct seasonal pattern, with the highest incidence of sheep and goat pox occurring in November and August, during the warm and cold moist months, and the lowest incidence in the hot, dry months of May [28]. This seasonality is corroborated by observations from Chad, where the disease is prevalent in both the cold dry season (December–February) and the hot humid season (June–July), albeit with variable mortality [2]. Several mechanisms likely underpin this pattern. Moisture and cooler temperatures may enhance environmental survival of the virus in scabs and fomites. Furthermore, these periods often coincide with seasonal livestock movements, congregation for markets, and the birthing season, all of which increase contact rates and stress-induced immunosuppression. The role of insect vectors is also hypothesized, as the cooler, humid conditions favor the activity of biting flies, which could serve as mechanical vectors, a transmission route increasingly recognized for capripoxviruses [2, 16]. Forecasting models based on Ethiopian data predict an increase in outbreak frequency for the period 2020-2026, signaling an urgent need for proactive, risk-based surveillance [28].

Host Species Susceptibility and Cross-Species Transmission

The classical dogma of strict host specificity for capripoxviruses has been substantially eroded by field and experimental evidence. While GTPV is the primary pathogen of goats, and SPPV of sheep, a significant body of evidence documents frequent and consequential cross-species infections. A comprehensive seroprevalence study in the Wolaita Zone of Southern Ethiopia found that sheep were nearly five times more likely to be seropositive for capripoxvirus antibodies than goats (AOR: 4.73; 95% CI: 1.39–15.99) [24]. This suggests that in co-grazing systems, sheep may act as highly susceptible sentinels or amplifiers of pox viruses, including GTPV. This is further supported by findings from Northwest Ethiopia, where molecular characterization of clinical samples from suspected outbreaks revealed that sheep were frequently infected with goat pox virus specifically, not SPPV [18]. In Uganda, a large-scale serosurvey of 1,515 animals also found seropositivity to be higher in sheep (12%) compared to goats (10%), though the difference was less pronounced at the univariate level [12].

The biological basis for this cross-species vulnerability is rooted in the antigenic and genomic similarity of the viruses. The nucleotide sequence identity across the three capripoxvirus species can reach up to 97% [9]. This similarity allows for frequent spillover events. Critically, the directionality of transmission is not always conserved; some capripoxvirus strains appear to be true generalists, readily infecting both sheep and goats [14]. This has profound implications for vaccination strategies, as a vaccine derived from one species may need to be used to protect another. Indeed, the heterologous use of GTPV vaccines to protect cattle against LSDV is a well-established practice [1, 13, 15]. However, this immunological cross-protection also creates challenges for serological surveillance, as standard tests cannot distinguish between antibodies elicited by infection with GTPV, SPPV, or LSDV [9]. Using a GTPV vaccine in cattle, for instance, makes them seropositive on standard capripox ELISAs, complicating the differentiation of infected from vaccinated animals (DIVA) [9].

Intrinsic Risk Factors: Age, Sex, and Immunity

Among the most consistently identified intrinsic risk factors for GTPV infection are age and sex, with their effects being mediated by the complex dynamics of passive and active immunity. Study after study converges on the finding that younger animals are at significantly higher risk. In the Multan and Bahawalnagar regions of Pakistan, PCR-based detection rates were 25% and 31.25% in infant goats (2-10 months), respectively, compared to only 14.2% and 11.1% in adults [8]. Similarly, in Egypt, goats less than six months old exhibited higher antibody titers following natural exposure than older animals, correlating with a higher susceptibility to infection [10]. The Ugandan study identified age as an independent risk factor in multivariable analysis (OR: 0.43; 95% CI: 0.21–0.87), with younger animals being more likely to be seropositive [12]. This pattern is explained by the critical window of vulnerability that occurs when maternally derived antibodies (MDA) wane but the animal's own adaptive immune system is not yet fully primed. A definitive study on Saanen goat kids revealed that animals receiving colostrum from vaccinated does had detectable MDA up to 100-120 days of age, with the first seronegative individuals appearing at 56 days [23]. This period between 56 and 120 days represents a high-risk window where passive protection has faded, making early-life vaccination crucial. For adult animals, the primary risk factor is often the waning of vaccine-induced immunity over time if booster vaccinations are not administered.

The role of sex as a risk factor is more nuanced but often statistically significant. Several large studies have identified females as being at greater risk. The Ethiopian study in the Amhara region found that female animals had higher odds of seropositivity in multivariable logistic regression (p < 0.05) [30]. The Southern Ethiopian study reported a seroprevalence of 7.45% in females compared to lower rates in males [24]. In Uganda, sex was an independent risk factor, with females showing higher seropositivity (OR: 2.14; 95% CI: 1.31–3.5) [12]. This predisposition may be linked to the physiological stresses of pregnancy, parturition, and lactation, which can induce a state of relative immunocompromise, increasing susceptibility to viral infection. Additionally, the practice of retaining females for breeding over multiple seasons means they have a longer cumulative exposure period within an endemic environment.

Management and Environmental Factors: Herd Dynamics and Biosecurity

Herd-level and environmental factors are powerful determinants of GTPV transmission, often overshadowing individual animal risks. Flock size and body condition are consistently strong predictors. In Southern Ethiopia, large-sized flocks were over six times more likely to be seropositive compared to small flocks (AOR: 6.73; 95% CI: 1.58–28.67) [24]. Larger flocks inherently involve higher animal density, which facilitates direct contact transmission via infectious aerosols, ocular-nasal discharges, and contact with skin lesions [2, 16]. Nutritional status is a proxy for immune competence; animals in poor body condition were found to have a staggering 31.58% seroprevalence compared to those in good condition [24]. Stress from malnutrition, concurrent parasitic infections like tick infestation (also identified as a risk factor with 10.38% seroprevalence), and poor husbandry amplify susceptibility [24].

The physical environment is a reservoir for the virus. GTPV is notoriously hardy, capable of surviving for up to six months in dried scabs that slough off into the environment [2]. This persistence allows for indirect transmission via contaminated fomites such as feed troughs, water sources, bedding, and even the clothing of herders. Airborne transmission over short distances is possible, and the inhalation of dust contaminated with infectious scab material has been documented [2]. The efficacy of biosecurity measures, specifically disinfection, is critical. Research in Tajikistan demonstrated that common disinfectants like sodium hydroxide and commercial agents such as Dexid-400 and GAN possess high virucidal activity against capripoxviruses [20]. Therefore, the lack of routine cleaning and disinfection in livestock buildings, a common feature in many endemic regions, constitutes a major risk factor for the maintenance and amplification of viral loads within a herd.

Trade, Animal Movement, and Vaccination Status

The single most important anthropogenic driver for the long-distance dissemination of GTPV is the legal and illegal movement of live animals. This vector was unequivocally identified in the re-emergence of goat pox in Vietnam, where the virus was traced genetically to South China, likely following trade routes [3]. In Chad, the introduction of the virus into naïve herds is almost exclusively linked to the purchase or introduction of new animals without quarantine [2]. The study from Northwest Ethiopia provided stark quantitative evidence: in the absence of free animal movements, the disease was 95% less likely to occur (OR = 0.05; 95% CI: 0.02, 0.15) [18]. The practice of gifting animals, a common cultural and social custom in many African and Asian communities, was also identified as a significant risk factor in the Ugandan study, as it bypasses standard market health checks [12]. The European re-emergence of sheep and goat pox in Greece and Bulgaria in 2024-2025 was similarly fueled by uncontrolled and authorized animal movements, creating a complex epidemiological network that defied rapid containment [25].

Vaccination status is the single most controllable, and thus most critical, modifiable risk factor. The protective effect of vaccination is profound. In the Wolaita zone of Ethiopia, seroprevalence among unvaccinated animals was 5.17%, highlighting the absolute baseline risk in an endemic area [24]. However, the effectiveness of vaccination is dependent on numerous variables including strain match, potency, cold chain maintenance, and timing. The presence of MDA is a major confounder; administering the first vaccine dose before 100-120 days of age risks neutralization by maternal antibodies, resulting in vaccine failure [23]. Conversely, using an inappropriate vaccine strain can have catastrophic consequences. For instance, using a monovalent SPPV vaccine in goats may fail to protect against a heterologous GTPV challenge, as demonstrated by experiments where sheep vaccinated with a goat pox monovalent vaccine showed significant local reactions and one case of generalized disease [26]. The use of live attenuated vaccines, such as the G20-LKV strain originally developed for goats, is now widely used heterologously to protect cattle against LSDV and sheep against SPPV [1, 13]. However, the simultaneous administration of multiple live vaccines (e.g., SGP with PPR and bluetongue vaccines) can lead to immunological interference, reducing antibody titers to below protective thresholds [27, 29]. Thus, the risk factor is not just "vaccination vs. non-vaccination," but rather "appropriate, timely, and potent vaccination" vs. any deviation from that standard.

Clinical Manifestations and Pathological Lesions of Capripoxvirus in Goats

The clinical manifestations of goat pox virus (GTPV) infection in goats represent a complex, multisystemic disease process that reflects the profound pathogenicity of this capripoxvirus (CaPV) within the Poxviridae family. Capripoxviruses, as notifiable agents classified by the World Organisation for Animal Health (WOAH), are among the most economically devastating pathogens affecting small ruminant production systems across Africa, Asia, and the Middle East [2, 5, 16]. The disease manifests along a spectrum ranging from localized, benign eruptions to a severe, generalized, and frequently fatal systemic infection. The pathophysiological progression of GTPV is driven by viral replication within endothelial cells, macrophages, and epithelial cells, leading to characteristic proliferative and necrotic lesions that define the clinical picture [14, 16].

Incubation Period and Prodromal Phase

Following natural exposure, typically via aerosol inhalation, direct contact with infected animals, or fomites contaminated with virus-laden scabs, the incubation period for goat pox generally spans 4 to 14 days, contingent upon viral strain virulence, infective dose, and host immune status [2, 16]. The virus initially replicates at the site of entry, primarily within the respiratory mucosa or skin abrasions, before disseminating via the lymphatics and bloodstream to establish a primary viremia.

The prodromal phase, lasting 1 to 3 days, is often subtle in goats but is characterized by a marked biphasic fever, often exceeding 40–41.5°C (104–107°F). Concomitantly, affected animals exhibit pronounced lethargy, anorexia, depression, and a reluctance to move. Ocular and nasal mucous membranes become hyperemic and congested. A serous to mucopurulent nasal discharge emerges, which is highly infectious, as the virus is shed profusely in these secretions [2, 16]. This period of systemic disturbance is a critical window for viral dissemination within a herd, as infected animals are actively shedding virus before the appearance of pathognomonic skin lesions.

The Exanthematous Phase: Cutaneous and Mucosal Lesions

The pathognomonic feature of goat pox is the development of a generalized papular-pustular rash, which follows a predictable temporal and morphological sequence. This exanthem is the clinical hallmark that enables field diagnosis, though its severity varies dramatically between individual animals and outbreaks.

Macules and Papules: Approximately 24–48 hours after the onset of fever, erythematous macules (areas of reddened skin 0.5–1.0 cm in diameter) appear, most prominently on sparsely haired or hairless skin regions. These rapidly evolve into firm, raised, circumscribed papules. In goats, the predilection sites for initial and most severe lesion development are the perineum, scrotum, udder, medial thighs, axillae, periocular skin, muzzle, and lips [2, 14, 16]. The papules are typically 0.5 to 2.0 cm in diameter, though coalescing lesions can form larger plaques. Palpation of these papules reveals a firm, indurated texture, reflecting underlying dermal edema, cellular infiltration, and vascular thrombosis.

Vesicles, Pustules, and Scabs: Unlike in sheep pox, where vesicle formation is more pronounced, the papules in goats often undergo a rapid, sometimes attenuated, vesicular stage. The clear fluid within the vesicles quickly becomes turbid, forming pustules. The pustules are initially tense but soon become umbilicated or flattened. Over the subsequent 7–14 days, these pustules desiccate, forming thick, dark brown to black scabs (crusts). These scabs are tenaciously adherent and contain extremely high concentrations of infectious virions, remaining viable in the environment for up to six months in dried scabs, a critical epidemiological factor for farm-to-farm transmission [2, 20]. Deep scabs may slough, leaving a depigmented, alopecic scar that can permanently damage the hide, rendering it worthless for the leather industry [22, 32]. In superinfected or severe cases, the underlying tissue may ulcerate, leading to chronic, non-healing wounds that attract flies and predispose to myiasis.

Distribution and Severity: The distribution of lesions is a key diagnostic feature. In severe, generalized cases, the eruption is profuse, covering large areas of the body. Lesions are almost invariably present on the mucous membranes of the oral cavity, nares, vulva, and prepuce. Oral lesions, papules, vesicles, and erosions on the tongue, gums, and hard palate, cause hypersalivation, drooling, and dysphagia, contributing to rapid weight loss [2]. Involvement of the nasal mucosa leads to serosanguinous to purulent nasal discharge, which can become crusted, obstructing the nares and forcing the animal to breathe through the mouth. Ocular involvement manifests as conjunctivitis, blepharitis, and keratitis, sometimes progressing to corneal opacity or ulceration. Lesions on the udder and teats of lactating does are particularly debilitating, leading to pain, refusal to allow suckling, and predisposition to secondary bacterial mastitis [2, 16]. Similarly, scrotal lesions in bucks can cause pain, swelling, and transient or permanent infertility due to testicular degeneration [31].

Respiratory and Systemic Manifestations

Beyond the dermatological signs, GTPV exerts a significant impact on the respiratory tract, which is a primary route of both entry and viral shedding. The development of nodular lesions in the lungs and upper respiratory tract is a common and serious sequela. During the viremic phase, the virus seeds the pulmonary parenchyma, leading to the formation of discrete, firm, greyish-white nodules (pox lesions) throughout the lung lobes. These lesions represent foci of proliferative and necrotic pneumonia. Clinically, this manifests as a progressive, non-productive cough, tachypnea, dyspnea, and labored abdominal breathing [16]. Auscultation reveals harsh lung sounds, crackles, and wheezes, indicative of extensive pulmonary consolidation and inflammation. Severe respiratory compromise is a leading cause of mortality in peracute and acute cases.

Generalized lymphadenopathy is almost universally present. The superficial lymph nodes, particularly the submandibular, prescapular, and prefemoral nodes, become palpably enlarged, firm, and painful on manipulation. This reflects the intense lymphoproliferative response and viral replication within lymphoid tissue throughout the body.

Pathological Lesions: Gross and Histopathological Findings

The macroscopic and microscopic pathology of goat pox mirrors the clinical progression and provides definitive evidence of the disease.

Gross Pathology: At necropsy, the most striking findings are the cutaneous and mucocutaneous lesions described above. Upon incision, the papules are found to be firm, greyish-white to yellowish, and extend from the epidermis deep into the dermis and subcutaneous tissue. In animals that succumb to the disease, the lungs are heavy, edematous, and fail to collapse. Multiple discrete, firm, greyish-white nodules, measuring 0.5 to 3.0 cm in diameter, are scattered throughout all lung lobes, often with a surrounding zone of congestion or hemorrhage. These nodules are homologous to the skin papules (so-called "lung pox"). Histologically, these are foci of coagulative necrosis surrounded by a zone of intense inflammation [22].

The respiratory mucosa (trachea and bronchi) may show similar nodular lesions or diffuse erythema. The abomasum and rumen may exhibit ulcerative lesions, though this is less consistent than the pulmonary findings. Splenomegaly, hepatomegaly with occasional necrotic foci, and hemorrhagic lymphadenitis are frequently observed in acute fatalities.

Histopathology: The histological hallmarks of CaPV infection are characteristic inclusion bodies and specific cellular changes. The pathognomonic microscopic lesion is the Guarnieri-like inclusion body, an eosinophilic, intracytoplasmic structure found within infected epithelial cells, macrophages, and endothelial cells [14, 22]. These inclusions represent sites of viral replication (viral factories) and are a key diagnostic feature.

The evolution of a skin papule is a study in progressive pathology:

1. Proliferative Phase: Early lesions show hyperplasia of the stratum spinosum (acanthosis) and ballooning degeneration of keratinocytes. Affected cells undergo striking enlargement (ballooning degeneration), often losing their nuclei and becoming vacuolated. Intracytoplasmic eosinophilic inclusion bodies are prominent.
2. Necrotic Phase: As the lesion matures, there is widespread coagulative necrosis of the epidermis and superficial dermis. This necrotic core is surrounded by a dense inflammatory infiltrate composed of macrophages, lymphocytes, and neutrophils. The underlying dermis shows severe edema, vascular hyperplasia, and thrombosis of small blood vessels, leading to ischemic infarction of the overlying skin. This vascular thrombosis is the pathological basis for the "pox" lesion’s firm, ischemic appearance.
3. Resolution Phase: The necrotic epidermis and inflammatory debris form the thick scab. Re-epithelialization occurs beneath the scab, driven by regenerative cells from the surrounding intact epithelium.

In the lungs, the histological picture is that of a severe, multifocal, proliferative and necrotic bronchointersitial pneumonia. The characteristic "lung pox" nodules are sharply demarcated areas of coagulative necrosis, surrounded by a zone of macrophages, many of which contain typical intracytoplasmic inclusion bodies. The alveolar septa are thickened by edema and inflammatory cell infiltration. Secondary bacterial bronchopneumonia is a common terminal complication, especially in animals debilitated by severe skin disease.

Morbidity, Mortality, and Economic Implications

The clinical impact of goat pox is staggering. Morbidity rates in susceptible naive populations can approach 75–100%, reflecting the extreme contagiousness of the virus [16]. Mortality rates are highly variable, ranging from 5–10% in enzootic regions with older, partially immune animals, to 50–85% or even 100% in young kids or immunologically naive herds experiencing a primary outbreak [3, 16, 18]. The severity is profoundly influenced by age, nutritional status, breed, and the presence of concurrent infections or stressors [12, 24].

The economic ramifications extend far beyond direct mortality. The severe damage to the hide and skin, as documented in central Ethiopia, renders the leather worthless, representing a catastrophic loss for the tanning and leather goods industry [32]. Losses in milk production, weight gain, and fertility, including abortion storms and permanent sterility in breeding stock, compound the financial devastation [2, 16, 31]. Strict trade restrictions imposed by WOAH on affected regions further cripple the livestock economy [2, 16].

Differential Diagnosis and Clinical Distinction

The clinical picture of goat pox can be confused with other eruptive diseases, though careful observation typically allows for differentiation. Contagious ecthyma (Orf virus) causes proliferative, crusty lesions primarily at the mucocutaneous junctions of the mouth and teats, but Orf lesions are rarely generalized and are not accompanied by the same degree of systemic illness, fever, or characteristic "pox" nodules on the skin and lungs. Peste des petits ruminants (PPR) causes severe stomatitis, diarrhea, and pneumoenteritis, but lacks the focal, raised papular skin eruption and intracytoplasmic inclusion bodies diagnostic of poxvirus. Dermatophilosis (cutaneous streptothricosis) presents with crusty, exudative lesions but is not associated with systemic fever or internal organ involvement. Molecular differentiation between GTPV and sheeppox virus (SPPV) in mixed-species flocks is now possible through advanced techniques such as high-resolution melting (HRM) PCR and multiplex real-time PCR, which can definitively identify the viral species and guide appropriate control measures [4, 7, 11, 21].

Diagnostic Approaches for GTPV: Serological and Molecular Detection

The accurate and timely diagnosis of goat pox virus (GTPV) infection is a cornerstone of effective disease surveillance, outbreak management, and the implementation of control strategies, including vaccination campaigns. Given the clinical similarities between GTPV, sheep pox virus (SPPV), and lumpy skin disease virus (LSDV), all members of the genus Capripoxvirus (CaPV) within the family Poxviridae, differential diagnosis is not merely an academic exercise but a practical necessity for guiding appropriate veterinary responses [4, 5, 17]. The genetic and antigenic relatedness of these viruses, with nucleotide sequence similarities reaching up to 97% among CaPV species, presents a formidable challenge for diagnostic differentiation [9]. Consequently, diagnostic approaches for GTPV have evolved from classical virological and serological methods to highly sophisticated molecular techniques, each with distinct advantages, limitations, and applications in different epidemiological contexts. This section provides an exhaustive examination of these methodologies, delving into their biological principles, operational mechanisms, and interpretive nuances as derived from the contemporary literature.

Serological Detection: Harnessing the Humoral Immune Response

Serological assays for GTPV are fundamentally predicated on the detection of antibodies produced by the host in response to natural infection or vaccination. The humoral immune response to CaPVs, including GTPV, is characterized by the appearance of virus-neutralizing antibodies (VNAs) approximately 15 days post-infection or vaccination, with peak titers typically observed between 21 and 30 days [17]. These antibodies, primarily of the immunoglobulin G (IgG) isotype, target viral surface proteins critical for host cell entry and are the basis for the two principal serological platforms: the virus neutralization test (VNT) and enzyme-linked immunosorbent assays (ELISA).

The Virus Neutralization Test: The Historical Gold Standard

The VNT has long been considered the gold standard for serological detection of GTPV due to its high specificity and functional relevance. This assay measures the functional capacity of serum antibodies to neutralize the infectivity of a live GTPV reference strain in a permissive cell culture system, such as Vero cells or primary lamb testis cells [8, 23, 24]. The principle involves incubating serial dilutions of heat-inactivated test serum with a standardized dose of infectious GTPV, followed by inoculation onto a susceptible cell monolayer. After an incubation period, the highest serum dilution that completely prevents the development of a cytopathic effect (CPE) or plaque formation is recorded as the neutralizing antibody titer. Results are often expressed as a virus neutralization index (VNI) or as the log10 of the reciprocal of the final dilution [19, 23].

The VNT provides a direct measure of protective immunity, as neutralizing antibodies are a key correlate of protection against poxvirus challenge. This makes the VNT indispensable for evaluating vaccine efficacy and for serosurveillance studies aimed at understanding population-level immunity. For instance, Abdollahi et al. [23] utilized the VNT to determine the persistence of maternally derived antibodies against GTPV in goat kids, establishing that the appropriate age for primary vaccination falls between 100 and 120 days, when VNIs become negative. Similarly, large-scale seroprevalence studies in Ethiopia and Uganda have relied on the VNT and its variant, the serum neutralization test (SNT), to estimate the prevalence of CaPV antibodies in sheep and goat populations, revealing seropositivity rates ranging from 4.95% in southern Ethiopia to 15.5% in the Amhara region [12, 24, 30]. The VNT is also employed to assess the immunogenicity of heterologous vaccines, such as those using GTPV strains to protect cattle against LSDV, where neutralizing antibody titers are a primary endpoint [1, 19]. Kassa et al. [24] and Shafik et al. [19] both demonstrated that SNT results correlate with protection, with higher titers associated with reduced clinical signs upon challenge.

However, the VNT is not without its limitations. It is a labor-intensive, time-consuming (requiring 5–10 days), and logistically demanding procedure that requires cell culture facilities, a continuous supply of susceptible cells, and the handling of live virulent virus, posing biosafety risks. Furthermore, the VNT is inherently slow for high-throughput applications and is subject to variability between laboratories due to differences in cell lines, virus strains, and endpoint determination criteria. Perhaps most critically for GTPV diagnostics, the VNT cannot reliably distinguish between antibodies elicited by GTPV, SPPV, or LSDV infection due to the extensive antigenic cross-reactivity within the genus [4, 9]. This lack of species-level specificity limits its utility in regions where multiple CaPVs co-circulate or where heterologous vaccination is practiced [1, 13].

Enzyme-Linked Immunosorbent Assays: High-Throughput and Versatile

ELISA has emerged as a more practical serological tool for large-scale epidemiological studies, offering superior throughput, speed, and ease of standardization compared to the VNT. Several ELISA formats have been developed for CaPV detection, most commonly indirect ELISAs (iELISAs) using whole-virus antigens or recombinant proteins, and competitive ELISAs (cELISAs) that use monoclonal antibodies to block the binding of serum antibodies to a specific viral epitope.

The Double CaPV multispecies antigen ELISA, for example, has been effectively applied in serosurveillance, as demonstrated by Gerald et al. [12] in Uganda, who used it to test over 1,500 serum samples from sheep and goats, achieving a 10% overall seropositivity. Similarly, Sareyyüpoğlu et al. [15] employed a commercially available CaPV ELISA to monitor the immune response in cattle vaccinated with SGP vaccines against LSD, demonstrating that the ELISA could detect antibody levels deemed protective after challenge.

A major advancement in serological diagnostics is the development of DIVA (Differentiating Infected from Vaccinated Animals) strategies. This is particularly relevant for GTPV, as its attenuated strains are increasingly used as heterologous vaccines against LSDV in cattle and buffaloes [1, 31]. Traditional ELISAs cannot distinguish an animal vaccinated with a live attenuated GTPV vaccine from one naturally infected with LSDV due to the high degree of antigenic similarity. To address this, Yuan et al. [9] developed a novel synthetic gene unique to LSDV, which encodes a protein not present in GTPV or SPPV. When used as the coating antigen in an iELISA, this recombinant protein specifically detects antibodies generated only during LSDV infection, yielding 100% diagnostic specificity and 93.3% sensitivity, with no cross-reactivity to sera from cattle vaccinated with GTPV vaccines [9]. This represents a paradigm shift in serological monitoring, enabling the safe and effective deployment of GTPV-based vaccines without compromising the ability to surveil for field LSDV infections.

Despite its advantages, the serological approach, whether VNT or ELISA, is fundamentally constrained by the temporal dynamics of the antibody response. Antibody titers rise over days to weeks post-infection, meaning serology is inherently retrospective and cannot diagnose an active, acute infection. Furthermore, maternal antibodies can confound serological results in young animals for up to 100–120 days, complicating both diagnostic interpretation and vaccination timing [23]. Therefore, while essential for prevalence studies and vaccine monitoring, serological methods are increasingly complemented by, and in acute cases, supplanted by, direct pathogen detection through molecular techniques.

Molecular Detection: Direct Pathogen Identification and Differentiation

The advent of polymerase chain reaction (PCR) and its derivatives has revolutionized the diagnosis of GTPV, enabling the direct detection of viral nucleic acid from a wide variety of clinical specimens, including skin scabs, papules, whole blood, and tissue biopsies [8, 10]. Molecular methods offer unparalleled sensitivity, specificity, and speed, often providing results within hours. Critically, they are the only reliable means of differentiating the closely related CaPV species at the genetic level [4, 5, 7].

Conventional PCR and Gel Electrophoresis

Conventional PCR, targeting specific genomic regions of CaPV, remains a widely used and cost-effective tool, particularly in endemic regions with limited resources. The most commonly employed genetic targets include the P32 gene (a homologue of the vaccinia virus H3L gene encoding a core envelope protein), the RPO30 gene (encoding the 30-kDa RNA polymerase subunit), and the GPCR gene (G protein-coupled receptor) [3, 5, 8, 11, 22].

Diagnostic PCR for GTPV can be species-specific or genus-specific. Genus-specific primers (e.g., targeting P32) can amplify a fragment from any CaPV, but amplicon size differences or subsequent restriction fragment length polymorphism (RFLP) analysis can sometimes differentiate species [4, 21]. More robust species identification is achieved through gene-specific PCR, where the size of the amplicon itself is distinct for each CaPV. The RPO30 gene is particularly valuable for this purpose. Mahmoud and Khafagi [11] demonstrated that a PCR targeting RPO30 yielded a 152 bp fragment for GTPV and a 172 bp fragment for SPPV, allowing direct visual differentiation of the two viruses by agarose gel electrophoresis. Ijaz et al. [8] successfully used P32 gene-specific primers to characterize GTPV from field outbreaks in Pakistan, identifying a higher prevalence in young goats. Similarly, Fares et al. [10] in Egypt used P32 and RPO30 primers to confirm the identity of GTPV isolates from clinical cases.

The advantages of conventional PCR include its relative simplicity, low cost per sample, and accessibility to laboratories in developing countries. However, it is less sensitive than real-time PCR, requires post-amplification processing (gel electrophoresis), which increases the risk of amplicon contamination, and provides only qualitative or semi-quantitative results. Moreover, RFLP analysis, while useful, is an additional time-consuming step.

Real-Time Quantitative PCR (qPCR) and Multiplexing

Real-time PCR (qPCR) has become the gold standard for the rapid and quantitative detection of GTPV in both clinical and research settings. The technique monitors the amplification of target DNA in real-time using fluorescent probes or DNA-binding dyes, eliminating the need for post-PCR processing and reducing turnaround time to 1–3 hours. qPCR is significantly more sensitive than conventional PCR, with detection limits as low as 0.1 TCID50/ml or 10² copies of the target genome, making it ideal for detecting low levels of viremia or viral shedding [4, 7].

A critical capability of qPCR is multiplexing, which allows simultaneous detection and differentiation of multiple CaPV species in a single reaction. Wang et al. [4] developed a triplex real-time PCR assay using universal CaPV primers in combination with specific TaqMan probes for LSDV, SPPV, and GTPV. This assay demonstrated 100% specificity with no cross-reactivity to other pathogens causing similar clinical signs (e.g., Orf virus, FMDV, Pasteurella spp.) and successfully identified the etiological agent in clinical samples from China and Ethiopia, with results perfectly concordant with RFLP-PCR and gene sequencing [4]. This multiplexing strategy is of immense practical value in regions experiencing outbreaks of unknown etiology, as it provides a definitive diagnosis within hours.

High-resolution melting (HRM) analysis represents a further refinement of qPCR technology. Pestova et al. [7] developed an HRM PCR assay targeting a 111 bp region of the LSDV010 ORF. The assay exploits subtle sequence differences between CaPV species that cause variations in the melting temperature (Tm) of the PCR amplicon. The resulting Tm profiles were highly specific: 73.61 ± 0.04°C for GTPV, 74.24 ± 0.06°C for SPPV, and 74.56 ± 0.04°C for field LSDV strains, allowing clear differentiation [7]. Remarkably, the assay could even discriminate between field and vaccine strains of LSDV, a feat of critical importance for post-vaccination surveillance. The HRM approach offers a simpler and potentially cheaper alternative to probe-based multiplexing, as it requires only a single fluorescent dye intercalator. However, it demands highly precise thermal control and standardized protocols.

Loop-Mediated Isothermal Amplification (LAMP)

LAMP is a revolutionary nucleic acid amplification technology that offers a rapid, specific, and simple alternative to PCR, particularly suited for field-based diagnostics and resource-limited settings. LAMP operates at a constant temperature (typically 60–65°C) using a specialized DNA polymerase (Bst polymerase) with strand-displacement activity. The reaction uses 4–6 primers recognizing 6–8 distinct regions on the target gene, resulting in exceptionally high specificity and the production of large amounts of DNA. The amplification product can be detected by visual inspection using turbidity or colorimetric dyes (e.g., SYBR Green or calcein), obviating the need for expensive thermal cyclers and gel electrophoresis systems [21].

Zhao et al. [21] pioneered the development of a LAMP assay for the differential detection of GTPV and SPPV, using three sets of primers designed against the inverted terminal repeat (ITR) sequences of the CaPV genome. The assay was performed at 62°C for 45–60 minutes and was 100% specific for GTPV and SPPV, showing no cross-reactivity with a range of other ovine and caprine pathogens, including Orf virus, FMDV, and various mycoplasmas and protozoa [21]. When validated against 135 preserved CaPV-positive clinical samples, the GTPV-specific LAMP primers achieved a 100% detection rate, while the SPPV LAMP primers detected 98.8% of SPPV-positive samples [21]. This performance underscores the potential of LAMP as a point-of-care diagnostic tool. Its key advantages include speed (results in under one hour), simplicity (requiring only a heat block or water bath), and robustness (tolerance to common PCR inhibitors found in clinical samples). The primary limitation is the complexity of primer design, although once optimized, the assay is highly reproducible.

Virus Isolation and Electron Microscopy

While molecular and serological methods are now predominant, classical virological techniques retain a role in specific contexts, particularly for the initial characterization of novel viral strains and for research purposes. Virus isolation involves inoculating clinical material (e.g., ground skin scab suspensions) onto susceptible cell lines such as Vero cells, lamb testis cells, or primary lamb kidney cells [3, 10, 11]. GTPV replication typically produces a characteristic CPE within 5–10 days, including cell rounding, detachment, and syncytia formation. Pham et al. [3] successfully isolated GTPV from Vietnamese field samples by culturing skin scabs on Vero cells, providing the viral material for subsequent molecular and phylogenetic characterization.

Another classical isolation method is the inoculation of the chorioallantoic membrane (CAM) of 11–13-day-old embryonated chicken eggs. This technique yields characteristic pock lesions (focal, white, opaque plaques) indicative of poxvirus replication, as demonstrated by Fares et al. [10] and Mahmoud and Khafagi [11], who observed typical pock lesions in 66–81% of inoculated samples. For definitive identification, transmission electron microscopy (TEM) of negatively stained preparations provides direct visualization of the brick-shaped or oval-shaped poxvirus particles, measuring approximately 260–300 nm in length and 200–260 nm in width, with a characteristic surface pattern of globular filaments [11]. However, TEM requires highly specialized and expensive equipment, skilled personnel, and cannot differentiate between CaPV species [11, 16].

These traditional methods are invaluable for generating high-titer viral stocks for vaccine development and for detailed molecular analyses. However, their use in routine diagnostics is severely limited by their lengthy turnaround times (10–14 days), the requirement for specialized cell culture or egg facilities, and their lower sensitivity compared to molecular methods [16].

Integrated Diagnostic Strategies for GTPV

In contemporary veterinary practice, the most effective diagnostic approach for GTPV involves the strategic integration of clinical observation, serology, and molecular testing, guided by the specific diagnostic objective. For the initial investigation of an acute outbreak with characteristic nodular and necrotic skin lesions, the diagnostic pathway should prioritize rapid pathogen detection. In such cases, the collection of skin scabs, crusts, or papules is the sample of choice, as these tissues contain the highest viral loads [2]. Nucleic acid extracted from these samples can be subjected to a real-time PCR assay, preferably a multiplex qPCR or HRM-PCR, to simultaneously confirm the presence of a CaPV and specifically identify it as GTPV, SPPV, or LSDV [4, 7]. This approach provides a definitive, species-level diagnosis within hours, enabling the immediate implementation of appropriate control measures (e.g., quarantine, vaccination with a homologous or heterologous strain, movement restrictions) as outlined by the World Organisation for Animal Health (WOAH) [16, 28].

For serosurveillance and vaccination monitoring, serological methods are the method of choice. Given the cross-reactivity of whole-virus antigens, a cELISA or a multispecies iELISA is ideal for initial screening to determine the overall prevalence of CaPV exposure in a population [12, 30]. If the objective is to differentiate natural infection from vaccination in a herd, a DIVA-compatible iELISA, such as the one developed by Yuan et al. [9] using a synthetic LSDV-specific antigen, is essential. The VNT remains the standard for quantifying functional neutralizing antibodies to assess vaccine efficacy and protective immunity [1, 19, 23]. In instances of serological positivity in a previously vaccinated herd, molecular testing of any suspicious skin lesions should be performed to rule out breakthrough infections by a field strain.

For molecular epidemiological studies and phylogenetic tracing of outbreak origins, the integration of conventional PCR with gene sequencing is indispensible. Amplification and sequencing of multiple genetic markers, such as the P32, RPO30, and GPCR genes, provides the high-resolution data necessary to construct phylogenetic trees, understand viral evolution, and infer transmission routes [3, 5, 22]. For instance, Pham et al. [3] used P32 gene sequencing to reveal that the re-emerging GTPV strain in Vietnam had >99% nucleotide identity with strains from China, India, and Pakistan, strongly suggesting a common Asian origin. This kind of molecular intelligence is critical for informing transboundary disease control strategies and for the early detection of emerging recombinant strains, such as the KSGP-like LSDV variants that now circulate in parts of Asia [33].

In conclusion, the diagnostic landscape for GTPV is characterized by a powerful and diverse arsenal of tools. While serological methods provide essential insights into population immunity and vaccine performance, they are fundamentally limited in their ability to diagnose acute disease or differentiate closely

Immunity and Vaccination Strategies: Maternal Antibody Interference and Vaccine Timing

The development of effective vaccination protocols against goat pox virus (GTPV) is profoundly complicated by the interplay between passively acquired maternal immunity and the ontogeny of the neonatal immune system. This dynamic represents one of the most critical, yet frequently underestimated, determinants of vaccine efficacy in young ruminants. For capripoxviruses, which are classified as notifiable by the World Organisation for Animal Health (WOAH) and cause significant economic losses across Africa, Asia, and parts of Europe, the failure to properly time vaccination in the face of maternal antibody interference can lead to widespread vaccine failure, leaving entire cohorts of young animals susceptible to a disease with morbidity rates reaching 75–100% in endemic areas and mortality that can approach 100% in naive populations [16, 17]. Understanding the precise kinetics of maternal antibody decay, the mechanisms by which these antibodies neutralize vaccine virus, and the strategic windows for intervention is therefore not merely an academic exercise but a cornerstone of effective disease control programs.

The Dynamics of Passive Immunity in Goat Kids

The foundation of neonatal protection against GTPV rests upon the efficient transfer of colostral immunoglobulins from vaccinated or previously infected does to their offspring. This passive immunity is critical for survival during the first weeks of life, yet it simultaneously creates a formidable barrier to active immunization. The seminal work by Abdollahi et al. (2024) provides the most comprehensive characterization of this phenomenon in goats, utilizing a controlled experimental design with Saanen kids receiving colostrum from vaccinated does [23]. Their longitudinal study, employing the virus neutralization test (VNT) at 11 time points from birth to 120 days, revealed a remarkably predictable decay curve. All kids in the treatment group were seropositive at birth, reflecting the efficient absorption of colostral antibodies. The first seronegative individuals appeared at 56 days of age, but critically, the average virus neutralization index (VNI) for the group did not become negative until between 100 and 120 days of age [23]. This finding establishes a crucial benchmark: the complete waning of maternally derived neutralizing antibodies in goat kids occurs approximately 3.5 to 4 months post-partum.

This temporal window is biologically significant. The half-life of passively acquired IgG in ruminants is typically 2–3 weeks, but the persistence of detectable neutralizing titers for over 100 days suggests either a high initial titer in the colostrum of vaccinated does or a slower catabolic rate for capripoxvirus-specific antibodies. The implications are profound. Vaccinating a kid at 2 months of age, when a substantial proportion of the cohort still harbors neutralizing antibodies, risks the vaccine virus being neutralized before it can replicate sufficiently to stimulate a protective adaptive immune response. This phenomenon, known as maternal antibody interference, is the single most common cause of early-life vaccine failure in livestock. The data from [23] strongly suggest that the optimal window for primary vaccination against GTPV is between 100 and 120 days of age, a recommendation that directly contradicts the common, but empirically unsupported, practice of vaccinating at 2–3 months.

Epidemiological Correlates and the Window of Susceptibility

The biological data on maternal antibody decay are corroborated by field epidemiological studies that consistently identify age as a significant risk factor for GTPV infection. Multiple cross-sectional seroprevalence surveys across endemic regions, including Ethiopia, Uganda, and Pakistan, have demonstrated that young animals are at disproportionately higher risk. Fentie et al. (2017) in the Amhara Region of Ethiopia found that young animals were at significantly higher risk of seropositivity compared to adults (p < 0.05), a finding that initially seems paradoxical [30]. However, this seropositivity in young animals likely reflects either recent natural infection or, more tellingly, the residual presence of maternal antibodies that are waning but still detectable. Conversely, studies focusing on clinical disease rather than serology paint a clearer picture. Ijaz et al. (2019) in Pakistan reported that infant goats (2–10 months) in Multan and Bahawalnagar showed clinical positivity rates of 25% and 31.25%, respectively, compared to only 14.2% and 11.1% in adults [8]. This stark disparity underscores the vulnerability of the post-maternal immunity, pre-vaccination window.

This period, roughly from 2 to 4 months of age, represents a high-risk "immunity gap." The kid has lost the protective umbrella of maternal antibodies but has not yet developed its own active immunity through vaccination or natural exposure. The epidemiological data from Uganda further refine this picture. Gerald et al. (2025) demonstrated that age was independently associated with seropositivity (OR 0.43, p = 0.019), with younger animals showing a different risk profile than adults [12]. Similarly, Kassa et al. (2024) in Southern Ethiopia found that older animals (>2 years) had higher seroprevalence (8.33%) than younger cohorts, likely reflecting cumulative exposure over a lifetime [24]. The convergence of these field data with the controlled experimental data from [23] is compelling: the first 100 days of life are dominated by passive immunity, followed by a period of heightened susceptibility that extends until active immunity is established through appropriately timed vaccination.

Vaccination Strategies to Overcome Maternal Interference

Given the established kinetics of maternal antibody decay, the strategic question becomes how to design vaccination protocols that minimize the interference window. The evidence from [23] provides a clear, evidence-based recommendation: the first dose of GTPV vaccine should be administered at 100–120 days of age. This timing ensures that the vast majority of kids have seroconverted to negative status, allowing the live attenuated vaccine virus to replicate unimpeded and induce a robust, long-lasting immune response. However, this recommendation must be contextualized within the broader realities of herd management and the specific vaccine product used.

The type of vaccine and its antigenic composition also play a role. Live attenuated vaccines, which are the standard for capripoxvirus control, rely on limited replication in the host to stimulate immunity. This replication is exquisitely sensitive to the presence of neutralizing antibodies. In contrast, inactivated or subunit vaccines, while safer, are less immunogenic and require adjuvants and booster doses. The current landscape is dominated by live attenuated strains, including the G20-LKV strain of GTPV, which has been shown to be protective in cattle against lumpy skin disease virus (LSDV) at doses ranging from 15,000 to 80,000 TCID50 [1]. The same strain has demonstrated high immunogenicity in sheep against sheep pox virus, inducing high titers of viral neutralizing antibodies and providing complete protection against virulent challenge [13]. These findings highlight the cross-protective potential of capripoxvirus vaccines, but they also underscore the need for careful dose optimization, particularly in young animals where the immune system is still maturing.

The concept of heterologous vaccination is particularly relevant in regions where multiple capripoxviruses co-circulate. The antigenic similarity between GTPV, SPPV, and LSDV, with nucleotide sequence identity up to 97%, allows for the use of GTPV-based vaccines to protect against LSDV in cattle and buffalo [1, 9, 31]. Abulaiti et al. (2025) demonstrated that a live attenuated GTPV vaccine induced a considerable antibody titer in crossbred buffaloes, with sustained levels for over 150 days before declining by 300 days, without adversely affecting health or production parameters [31]. This cross-protection is a powerful tool, but it introduces additional complexity for vaccine timing in mixed-species herds. The same principles of maternal antibody interference likely apply across species, although the precise kinetics may vary.

Simultaneous Vaccination and Immunological Interference

A further layer of complexity arises from the common practice of administering multiple vaccines simultaneously to reduce labor and handling stress. This is a pragmatic necessity in many production systems, but it carries the risk of immunological interference. Sareyyüpoğlu et al. (2022) investigated the simultaneous administration of foot-and-mouth disease (FMD), peste des petits ruminants (PPR), sheep pox and goat pox (SGP), and bluetongue (BT) vaccines in sheep [27]. Their results were sobering: antibody titers for each vaccine agent decreased by 60 days post-vaccination (DPV) when administered simultaneously, with the difference being statistically significant for BTV and PPR vaccines (p < 0.05). The authors attributed this interference to several mechanisms, including competition for antigen-presenting cells, the induction of regulatory cytokines such as IL-10 by the SGP vaccine, and physical interference when multiple vaccines are injected at the same site [27]. This finding has direct implications for GTPV vaccination timing. If SGP vaccine is to be co-administered with other routine vaccines, the timing may need to be adjusted to ensure that the immune response to the capripoxvirus component is not compromised.

However, not all simultaneous vaccination strategies are detrimental. Sareyyüpoğlu et al. (2023) found that simultaneous vaccination of cattle with SGP and FMD vaccines provided an adequate protective immune response against LSDV challenge, with no detectable viral genome in blood or swabs of challenged animals [15]. This suggests that the degree of interference may be antigen-specific and dose-dependent. For GTPV specifically, the use of associated vaccines, combining attenuated strains of SPPV and GTPV in a single dose, has been shown to induce virus neutralizing antibodies in protective titers that did not differ from monovalent immunization [26]. This indicates that combining capripoxvirus strains is safe and effective, but combining them with unrelated live vaccines (e.g., PPR, BT) requires careful consideration of the vaccination schedule.

The Role of DIVA Strategies and Post-Vaccination Monitoring

The challenge of maternal antibody interference is compounded by the difficulty of serologically distinguishing vaccinated animals from those that have been naturally infected. This is a critical issue for disease surveillance and eradication programs. The development of DIVA (Differentiating Infected from Vaccinated Animals) strategies is therefore a high priority. Yuan et al. (2024) addressed this by developing a synthesized gene unique to LSDV for use in an indirect ELISA, which successfully differentiated cattle vaccinated with attenuated GTPV vaccine from those naturally infected with LSDV, achieving 100% diagnostic specificity and 93.3% sensitivity [9]. While this work focused on LSDV, the principle is directly applicable to GTPV. The ability to serologically distinguish vaccinated from infected animals would allow for more precise monitoring of vaccine coverage and the early detection of breakthrough infections, particularly in young animals where maternal antibodies might confound traditional serological tests.

Post-vaccination monitoring is essential to confirm that the chosen timing strategy is effective. Tuppurainen et al. (2021) emphasize that post-vaccination monitoring should be based on passive or active clinical surveillance in vaccinated herds [17]. In the context of maternal antibody interference, this means that if a cohort of kids vaccinated at 100–120 days subsequently experiences an outbreak, the timing protocol should be re-evaluated. WOAH guidelines recommend that vaccine seed viruses be confirmed using molecular methods, as there have been cases where the true identity of the vaccine virus was not what was believed [17]. This quality control step is particularly important when using heterologous vaccines (e.g., GTPV for LSDV control), as the immune response may differ from that induced by a homologous vaccine.

In conclusion, the timing of GTPV vaccination is a delicate balance between the waning of maternal immunity and the development of active protection. The evidence strongly supports a first vaccination window at 100–120 days of age, based on the decay kinetics of maternally derived neutralizing antibodies [23]. This recommendation is supported by epidemiological data showing heightened susceptibility in young animals [8, 12, 30] and by the demonstrated efficacy of live attenuated vaccines when administered to seronegative individuals [1, 13]. However, this timing must be adapted to local epidemiological conditions, the specific vaccine product, and the potential for interference from other simultaneously administered vaccines [27]. The integration of DIVA-capable diagnostic tools [9] and robust post-vaccination surveillance [17] will be essential to refine these recommendations and ensure that vaccination programs achieve their goal of reducing the devastating economic and animal welfare impacts of goat pox virus.

Control, Prevention, and Biosecurity Measures for Goat Pox

The multifaceted approach to controlling, preventing, and eradicating goat pox virus (GTPV) necessitates a comprehensive strategy that integrates rigorous biosecurity protocols, strategic vaccination campaigns, and rapid, accurate diagnostic surveillance. As a notifiable disease classified under the World Organisation for Animal Health (WOAH, formerly OIE) guidelines [5, 20], the economic and trade implications of GTPV are profound, causing significant losses in milk production, meat yield, hide quality, and reproductive performance [3, 24, 32]. The pathogen’s ability to persist in the environment, surviving up to six months in dried scabs [2], and its transmission via direct contact, fomites, and mechanical vectors such as insects [2, 17] demands a layered defense. Control measures must therefore target the virus at every stage of its transmission cycle, from the infected host to the contaminated environment.

Strategic Vaccination and Immunization Protocols

Vaccination remains the cornerstone of GTPV control, and the deployment of live attenuated vaccines has demonstrated robust efficacy in reducing morbidity, mortality, and viral shedding. The foundation of an effective vaccination program begins with understanding the kinetics of maternal antibody interference. Research by Abdollahi et al. (2024) [23] established that goat kids receiving colostrum from vaccinated does retained passive immunity for a critical window. Using the virus neutralization test (VNT), the study found that the first seronegative kids appeared at 56 days, with the average virus neutralization index (VNI) declining to negative between 100 and 120 days of age. This precise timing dictates that the primary vaccination dose should be administered at 100–120 days of age to avoid neutralization by maternally derived antibodies, thereby ensuring robust active immunization [23]. This principle is essential for optimizing herd immunity, particularly in endemic regions where neonatal mortality can be high.

The choice of vaccine strain is another critical consideration. The genus Capripoxvirus exhibits extensive antigenic cross-reactivity, allowing for the use of heterologous vaccines. The G20-LKV strain, derived from GTPV, has been extensively evaluated. Abitaev et al. (2022) [1] demonstrated that this strain, when used as a live attenuated vaccine in cattle, conferred complete protection against LSDV challenge at immunizing doses ranging from 15,000 to 80,000 TCID₅₀, with no adverse systemic reactions at lower dosages. Similarly, Kondibayeva et al. (2024) [13] showed that the G20-LKV strain provided high immunogenicity in sheep against virulent SPPV challenge, inducing protective titers of virus-neutralizing antibodies without clinical signs of sheep pox. This cross-protection is a powerful tool for regions co-circulating multiple capripoxviruses.

However, the safety profile of heterologous vaccines requires careful management. Konstantinov et al. (2018) [26] compared monovalent and associated (bivalent) vaccines containing attenuated strains of both SPPV and GTPV. While the associated vaccines induced protective antibody titers (3.50–4.05 log₂) without adverse effects, monovalent GTPV vaccination in sheep led to a large local reaction in three animals and a generalized form of sheep pox in one animal upon challenge with virulent SPPV. This underscores that while cross-protection is valuable, it is not absolute, and vaccine selection must be species-appropriate to avoid residual virulence or inadequate protection.

The immunological duration of protection is a further critical factor. In crossbred buffaloes vaccinated with a live attenuated GTPV vaccine against LSD, Abulaiti et al. (2025) [31] observed that antibody titers increased steadily post-vaccination, sustained for over 150 days before declining by day 300. This temporal profile informs booster schedules: annual or biannual revaccination is recommended for maintenance of herd immunity, particularly in high-risk zones. Additionally, the phenomenon of vaccine interference must be considered when polyvalent vaccination is attempted. Sareyyüpoğlu et al. (2022, 2023) [15, 27, 29] demonstrated that simultaneous administration of SGP vaccine with FMD, PPR, and bluetongue vaccines led to significantly decreased antibody responses by 60 days post-vaccination, particularly for BTV and PPR. This interference, likely due to cytokine modulation (e.g., IL-10 induction) and competition for immune resources, dictates that these live vaccines should be administered separately, with a recommended interval of at least 30 days [15, 27].

To address the issue of differentiating infected from vaccinated animals (DIVA), particularly relevant when using heterologous vaccines, advanced serological tools are being developed. Yuan et al. (2024) [9] created a synthesized gene unique to LSDV for use in an indirect ELISA. This assay achieved 93.3% diagnostic sensitivity and 100% specificity, with no cross-reaction against positive sera for other common bovine pathogens. While developed for LSDV, this principle is directly applicable to GTPV control, as it allows serosurveillance to distinguish true field infections from vaccine-induced antibodies, enabling targeted culling and movement control without compromising vaccination campaigns.

Biosecurity, Quarantine, and Environmental Control

Biosecurity measures are the second pillar of GTPV prevention. The virus is primarily transmitted via direct contact with infected animals, their secretions (nasal and ocular discharges), and desiccated scabs, which can remain infectious for up to six months in the environment [2]. Indirect transmission through contaminated fomites, such as feeding troughs, water sources, vehicles, and personnel, is a major risk factor, compounded by mechanical transmission by biting insects (e.g., mosquitoes and stable flies) which can carry the virus over short distances [2, 17]. The introduction of new animals into a flock is the most common inciting event, as demonstrated by epidemiological studies in Ethiopia and Uganda where animal movement, gifting, and trade were significant risk factors [12, 18].

Quarantine protocols must therefore mandate a minimum isolation period of 28 days for all incoming animals, during which they should be monitored for clinical signs (fever, papules, nodules) and serologically tested using validated assays such as virus neutralization or PCR-based methods [4, 5, 26]. The spatial and temporal clustering of outbreaks has been linked to animal density and movement patterns; Aregahagn et al. (2021) [28] reported that in Eastern Amhara, Ethiopia, outbreaks peaked in November and August (cold, moist months) but were lowest in hot, dry months. This seasonality suggests that vector activity and environmental survival are moderated by climate, and biosecurity efforts should be intensified during these high-risk windows.

Environmental decontamination is a critical but often overlooked component. The virucidal efficacy of common disinfectants against capripoxviruses has been rigorously tested. Atovullozoda et al. (2021) [20] demonstrated that GAN (a glutaraldehyde-based agent), Dexid-400 (a quaternary ammonium compound), and 2% sodium hydroxide (NaOH) exhibited high virucidal activity against the Variolaovium virus (sheep and goat pox causative agent) under field conditions in livestock buildings. In practice, premises should be thoroughly cleaned of organic matter (scabs, bedding, manure) before applying disinfectants, as organic material can neutralize chemical agents. For surfaces, a contact time of at least 30 minutes with 2% NaOH or a commercial virucidal disinfectant (e.g., 0.5% formaldehyde or 2% sodium hypochlorite) is recommended. Pastures should be rested for at least 30–60 days following an outbreak, as direct sunlight and desiccation can inactivate the virus on surfaces, but survival under scabs can be extended.

Movement Control, Culling, and Quarantine Zones

In the event of an outbreak, a rapid response protocol is essential. As detailed by Alexandrov et al. (2026) [25] in their modeling of the 2024–2025 European re-emergence, rapid detection and culling alone could control epidemics within 1–2 years in a naïve population, but nationwide vaccination combined with strict movement controls achieved eradication one year earlier. The core strategy involves the establishment of protection and surveillance zones around infected premises. All infected and in-contact animals must be humanely destroyed, with carcasses disposed of by rendering, deep burial, or incineration to prevent environmental contamination [16, 25]. Bedding, manure, and feed from infected pens should be composted at high temperatures or incinerated.

Movement control is particularly challenging due to the informal trade networks that often characterize small ruminant production in endemic regions. Kassa et al. (2024) [24] found that larger flock sizes (AOR 6.73) and poor body condition (31.58% seroprevalence) were significant predictors of seropositivity in Ethiopia, reflecting that larger, poorly managed flocks have higher contact rates and poorer biosecurity. Furthermore, Wondimu et al. (2021) [18] reported that in the absence of free animal movements, the disease was 95% less likely to occur (OR = 0.05). This highlights that enforcement of movement bans during outbreaks is the single most effective non-vaccine intervention. Enforcement should be coupled with compensation schemes to encourage farmer compliance and reporting.

Rapid Diagnosis and Surveillance as a Preventive Tool

Effective control is predicated on early detection. Clinical diagnosis alone is inadequate due to the near-identical presentation of sheep pox, goat pox, and LSD, and the potential for cross-species infection [3, 5, 11, 14]. Molecular diagnostics have revolutionized field-level detection. Multiplex real-time PCR assays, such as those developed by Wang et al. (2021) [4], can simultaneously detect and differentiate GTPV, SPPV, and LSDV with a limit of detection of 10² copies of target DNA, using specific probes targeting the P32 and RPO30 genes. Similarly, Pestova et al. (2018) [7] described a high-resolution melting (HRM) PCR assay that distinguishes GTPV (melting temperature 73.61°C) from SPPV (74.24°C) and vaccine versus field strains of LSDV, with analytical sensitivity down to 0.1 TCID₅₀/mL. These tools allow for same-day confirmation and species differentiation, which is critical for selecting the correct vaccine and implementing species-specific quarantine measures.

For resource-limited settings, loop-mediated isothermal amplification (LAMP) offers a rapid, low-cost alternative. Zhao et al. (2014) [21] developed a LAMP assay targeting the ITR sequences of capripoxviruses, achieving 100% detection rate for GTPV at 62°C within 45–60 minutes, with no cross-reactivity against other common small ruminant pathogens (Orf virus, FMDV, Mycoplasma spp.). This technology can be deployed at the pen-side or in regional laboratories with minimal equipment, enabling near-real-time decision-making for outbreak response.

Furthermore, phylogenetic surveillance is integral to long-term control. Studies from Vietnam [3], Saudi Arabia [5], and Pakistan [8] have demonstrated that circulating GTPV strains are geographically clustered, with the Vietnamese isolate (MN317561) sharing 99.6% nucleotide identity with South China strains, indicating transboundary spread. Continuous molecular monitoring allows for the early detection of novel strains or recombinant viruses, such as the KSGP lineage circulating in Asia [33], which may escape vaccine-induced immunity or exhibit altered pathogenicity. As highlighted by Fares et al. (2019) [10], routine PCR-based characterization using the P32 and RPO30 genes enables tracking of viral evolution and informs the selection of appropriate vaccine strains.

References

[1] Abitaev R, Kondibaeva ZB, Amanova Z, Sametova Z, Ussembay A, Bulatov Y. [Determination of the optimal immunizing dose of heterologous goat pox virus vaccine (Poxviridae: Chordopoxvirinae: Capripoxvirus) against lumpy skin disease].. Voprosy virusologii. 2022. DOI: https://doi.org/10.36233/0507-4088-116

[2] Kebkiba B. Risk factors of the introduction and spread of goat pox virus in the Republic of Chad. World Journal of Advanced Research and Reviews. 2022. DOI: https://doi.org/10.30574/wjarr.2022.14.2.0382

[3] Pham TH, Rahaman NYA, Lila M, Lai HLT, Nguyen LT, Nguyen GV, et al.. Molecular phylogenetics of a recently isolated goat pox virus from Vietnam. BMC Veterinary Research. 2021. DOI: https://doi.org/10.1186/s12917-021-02777-1

[4] Wang H, Kong Y, Mei L, Lv J, Wu S, Lin X, et al.. Multiplex Real-Time PCR Method for Simultaneous Detection and Differentiation of Goat Pox Virus, Sheeppox Virus, and Lumpy Skin Disease Virus.. Journal of AOAC International. 2021. DOI: https://doi.org/10.1093/jaoacint/qsab040

[5] El-Sabagh I, Al-Ali AM, Salem M, Al-Wsaibei HA, Al-Butayan AM, Housawi F. PHYLOGENETIC ANALYSIS OF SHEEP POX AND GOAT POX VIRUS STRAINS IN SAUDI ARABIA. Journal of Animal and Plant Sciences. 2020. DOI: https://doi.org/10.36899/japs.2020.3.0069

[6] Sun Z, Liu L, Zhang H, Li Y, Wei F, Li Z, et al.. Expression and functional analysis of Brucella outer membrane protein 25 in recombinant goat pox virus.. Molecular Medicine Reports. 2019. DOI: https://doi.org/10.3892/mmr.2019.9868

[7] Pestova Y, Byadovskaya O, Kononov A, Sprygin A. A real time high-resolution melting PCR assay for detection and differentiation among sheep pox virus, goat pox virus, field and vaccine strains of lumpy skin disease virus.. Molecular and Cellular Probes. 2018. DOI: https://doi.org/10.1016/j.mcp.2018.08.003

[8] Ijaz A, Jabeen F, Ashraf A, Naz S. Prevalence and PCR based molecular characterization of goat pox virus from field outbreaks of Multan and Bahawalnagar, Pakistan. Journal of Bio-Science. 2019. DOI: https://doi.org/10.3329/jbs.v28i0.44715

[9] Yuan X, Zhang H, Wang Y, Wu D, Shirani I, Chen Y, et al.. Development of a Synthesized Gene Unique to Lumpy Skin Disease Virus and Its Application in Serological Differentiation of Naturally Infected from Vaccinated Cattle with Attenuated Goat Pox Vaccine. Transboundary and Emerging Diseases. 2024. DOI: https://doi.org/10.1155/2024/7800855

[10] Fares M, Fawzy M, Shahin M, Elshahidy M. Isolation, and Molecular Identification of Goat Pox Virus in Suez Canal Area, Egypt. . 2019. DOI: https://doi.org/10.21608/scvmj.2019.69852

[11] Mahmoud M, Khafagi M. Detection, identification, and differentiation of sheep pox virus and goat pox virus from clinical cases in Giza Governorate, Egypt. Veterinary World. 2016. DOI: https://doi.org/10.14202/vetworld.2016.1445-1449

[12] Gerald N, Chrisostom A, Savino B, Franklin M, Dennis M, Patrick V, et al.. Seroprevalence and risk factors for sheep pox and goat pox among small ruminant herds from Nakapiripirit and Sembabule districts, Uganda. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1579164

[13] Kondibayeva Z, Amanova Z, Usembay AK, Abitaev R, Sametova Z, Turyskeldi SS, et al.. STUDY OF PROTECTIVE PROPERTIES AND INTENSITY OF INDUCING IMMUNITY OF THE VACCINE STRAIN G20-LKV OF GOAT POX DURING IMMUNIZATION OF SHEEP AGAINST SHEEP POX. Biosafety and Biotechnology. 2024. DOI: https://doi.org/10.58318/2957-5702-2023-16-38-47

[14] Sharma S, Nashiruddullah N, Ahmed JA. Pathology of Spontaneous Pox Virus Infection of Sheep and Goat in Jammu Region. International Journal of Current Microbiology and Applied Sciences. 2020. DOI: https://doi.org/10.20546/ijcmas.2020.906.150

[15] Sareyyüpoğlu B, Uzar S, Saraç F, Enül H, Adıay C, Çokçalışkan C, et al.. Immune response against lumpy skin disease after simultaneous vaccination of cattle with sheep pox and goat pox and foot and mouth disease vaccines.. Veterinary Microbiology. 2023. DOI: https://doi.org/10.1016/j.vetmic.2023.109726

[16] Zewdie G, Derese G, Getachew B, Belay H, Akalu M. Review of sheep and goat pox disease: current updates on epidemiology, diagnosis, prevention and control measures in Ethiopia. Animal Diseases. 2021. DOI: https://doi.org/10.1186/s44149-021-00028-2

[17] Tuppurainen E, Lamien C, Diallo A. Capripox (Lumpy Skin Disease, Sheep Pox, and Goat Pox). . 2021. DOI: https://doi.org/10.1002/9781119506287.CH28

[18] Wondimu A, Tassew H, Gelaye E, Hagos Y, Belay A, Teshome Y, et al.. Outbreak Investigation and Molecular Detection of Pox Virus Circulating in Sheep and Goats in Selected Districts of West Gojjam and Awi Zones Northwest, Ethiopia. Veterinary medicine. 2021. DOI: https://doi.org/10.2147/VMRR.S318549

[19] Shafik N, Khafagy H, Am A, Bassiuony AI, Zaki FF, Mikhael C, et al.. Comparative study between lumpy skin disease virus and sheep pox virus vaccines against recent field isolate of lumpy skin disease virus. Bionatura. 2021. DOI: https://doi.org/10.21931/rb/2021.01.03.12

[20] Atovullozoda R, Zhbanova S, Nazrullozoda S, Rajabaliya M, Odinaev KA, Bogomolova O, et al.. The effect of disinfectants on the sheep and goat pox virus in the environment and in livestock buildings. Athletic Therapy Today. 2021. DOI: https://doi.org/10.30917/ATT-VK-1814-9588-2021-1-3

[21] Zhao Z, Fan B, Wu G, Yan X, Li Y, Zhou X, et al.. Development of loop-mediated isothermal amplification assay for specific and rapid detection of differential goat Pox virus and Sheep Pox virus. BMC Microbiology. 2014. DOI: https://doi.org/10.1186/1471-2180-14-10

[22] Vitthal D, Bhupesh K, Shruti B, Divya S, Tejashri K, Barate A. Pathological studies and ORF 103 gene based molecular characterization of sheep pox virus from outbreaks in Maharashtra, India. Indian Journal of Animal Sciences. 2022. DOI: https://doi.org/10.56093/ijans.v92i10.110006

[23] Abdollahi M, Lotfi M, Lotfollahzadeh S, dezfouli MrM, Adibi M, Kamalzadeh M, et al.. Persistence of maternal antibodies against goat pox virus in goat kids. Journal of Veterinary Internal Medicine. 2024. DOI: https://doi.org/10.1111/jvim.17135

[24] Kassa F, Fesseha H, Mathewos M, Getachew S, Hundessa N, Aliye S, et al.. Seroprevalence and risk factors of sheep and goat pox virus in selected districts of Wolaita Zone, Southern Ethiopia. Journal of Veterinary Sciences. 2024. DOI: https://doi.org/10.4142/jvs.24086

[25] Alexandrov T, Baltusyte I, Broglia A, Calistri P, Gubbins S, Regge ND. Sheep and goat pox: vaccines and vaccination scenarios to control the epidemics in Greece and Bulgaria in 2025. EFSA journal. European Food Safety Authority. 2026. DOI: https://doi.org/10.2903/j.efsa.2026.9928

[26] Konstantinov AV, Starov SK, Diev V, Moroz NV, Kurnenkova EV, Basova DК, et al.. ANTIGENIC AND PROTECTIVE PROPERTIES OF EXPERIMENTAL ASSOCIATED VIRUS VACCINE AGAINST SHEEP POX AND GOAT POX. Veterinary Science Today. 2018. DOI: https://doi.org/10.29326/2304-196X-2018-2-25-42-46

[27] Sareyyüpoğlu B, Gülyaz G, Saraç F, Uzar S, Kabaklı Ö, Çokçalışkan C, et al.. Antibody response of sheep to simultaneous vaccination of foot-and-mouth disease, peste des petits ruminants, sheep pox and goat pox, and bluetongue vaccines.. Tropical biomedicine. 2022. DOI: https://doi.org/10.47665/tb.39.1.002

[28] Aregahagn S, Tadesse B, Tegegne B, Worku Y, Mohammed S. Spatiotemporal Distributions of Sheep and Goat Pox Disease Outbreaks in the Period 2013–2019 in Eastern Amhara Region, Ethiopia. Veterinary Medicine International. 2021. DOI: https://doi.org/10.1155/2021/6629510

[29] Sareyyüpoğlu B, Gülyaz V, Saraç F, Uzar S, Kabaklı Ö, Çokçalışkan C, et al.. Antibody response of sheep to simultaneous vaccine administration of foot and mouth disease, blue tongue, peste des pestits ruminants , and sheep-goat pox antigens. . 2021. DOI: https://doi.org/10.21203/rs.3.rs-881466/v1

[30] Fentie T, Fenta N, Leta S, Molla W, Ayele B, Teshome Y, et al.. Sero-prevalence, risk factors and distribution of sheep and goat pox in Amhara Region, Ethiopia. BMC Veterinary Research. 2017. DOI: https://doi.org/10.1186/s12917-017-1312-0

[31] Abulaiti A, Naseer Z, Ahmed Z, Tian S, Liu W, Shoaib M, et al.. Evaluation of antibody titer and associated risk factors of goat pox vaccine against lumpy skin disease in crossbred buffaloes. Veterinary research communications. 2025. DOI: https://doi.org/10.1007/s11259-025-10673-4

[32] Kenubih A, Mammo B, Terefe G, Fentahun T. Assessment of the Impact of Sheep and Goat Pox Lesions on Skin Quality in Selected Ware Houses of Central Ethiopia. Veterinary medicine. 2021. DOI: https://doi.org/10.2147/VMRR.S305705

[33] Sprygin A, Mazloum A, Schalkwyk Av, Krotova A, Bydovskaya O, Prokhvatilova L, et al.. Development and application of a real-time polymerase chain reaction assay to detect lumpy skin disease virus belonging to the Kenyan sheep and goat pox group. BMC Research Notes. 2023. DOI: https://doi.org/10.1186/s13104-023-06502-z